Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Invested Capital (2020 - 2025)

Apellis Pharmaceuticals has reported Invested Capital over the past 6 years, most recently at $463.8 million for Q4 2025.

  • Quarterly results put Invested Capital at $463.8 million for Q4 2025, up 102.95% from a year ago — trailing twelve months through Dec 2025 was $463.8 million (up 102.95% YoY), and the annual figure for FY2025 was $463.8 million, up 102.95%.
  • Invested Capital for Q4 2025 was $463.8 million at Apellis Pharmaceuticals, down from $494.7 million in the prior quarter.
  • Over the last five years, Invested Capital for APLS hit a ceiling of $494.7 million in Q3 2025 and a floor of -$141.5 million in Q2 2021.
  • Median Invested Capital over the past 5 years was $234.7 million (2023), compared with a mean of $239.3 million.
  • Biggest five-year swings in Invested Capital: crashed 160.97% in 2021 and later skyrocketed 794.8% in 2022.
  • Apellis Pharmaceuticals' Invested Capital stood at $198.7 million in 2021, then decreased by 14.49% to $169.9 million in 2022, then grew by 14.51% to $194.5 million in 2023, then rose by 17.49% to $228.5 million in 2024, then surged by 102.95% to $463.8 million in 2025.
  • The last three reported values for Invested Capital were $463.8 million (Q4 2025), $494.7 million (Q3 2025), and $156.3 million (Q2 2025) per Business Quant data.